Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome

Cerebral ischaemia initiates an inflammatory response in the brain [1] that is associated with induction of a variety of cytokines, including interleukin-6 (IL-6), a pleiotropic cytokine involved in diverse inflammatory functions. IL-6 mRNA and bioactivity are induced rapidly in experimental focal cerebral ischaemia [2, 3], and elevated IL-6 concentrations in cerebrospinal fluid (CSF) of acute stroke patients correlate with infarct volume [4]. However, the role of IL-6 in the central nervous system (CNS) following experimental cerebral ischaemia is not resolved [2, 3, 5, 6].

Systemic inflammatory responses are also evident following inflammation in the CNS, but the relationship between peripheral mediators and CNS events is uncertain [7]. Peripheral infection, which commonly precedes or complicates stroke [8, 9], is also a major stimulus for production of cytokines and an acute phase response. Although most cytokines are only present at biologically effective concentrations at the site of inflammation, IL-6 is a major circulating cytokine produced in response to inflammatory insult and infection, and is a potent stimulus for production of hepatic acute phase proteins [10], induction of fever [11], and activation of the hypothalamic-pituitary-adrenal (HPA) axis [12].

The relationship between peripheral inflammatory markers and outcome in stroke patients remains poorly understood. In patients with acute ischaemic stroke, some studies have reported an association between circulating IL-6 concentration and brain infarct volume, stroke severity, or outcome up to 6 months [13‐17]. Conversely, other studies have reported no association between serum IL-6 concentration and infarct volume or stroke severity at 3 months [4, 18]. Other markers of the acute phase response have also been implicated in the pathophysiology and outcome following ischaemic stroke [19‐26]. However, very few studies have related the magnitude of the peripheral inflammatory response in the first week to measures of severity of ischaemic insult or clinical outcome.

We have recently reported the kinetics of peripheral inflammatory markers in ischaemic stroke patients prospectively recruited within 12 hours of symptom onset, compared to controls matched for age, sex and degree of atherosclerosis [27]. The aim of the present study was to examine the relationship between the magnitude of the peripheral inflammatory response, as determined by peak values of plasma IL-6 or other peripheral inflammatory markers (peak plasma C-reactive protein (CRP), white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), plasma cortisol concentration and aural temperature) in the first week of stroke, with either severity of ischaemic insult, or long-term outcome.

The study was approved by the Local Research Ethics Committee. Consecutive patients aged over 18 years presenting with a clinical diagnosis of acute stroke, with suspected symptom onset within the preceding 12 hours, were screened prospectively. Patients were excluded if the time of symptom onset could not be reliably determined from the patient or witness. Patients with rapid improvement of symptoms between onset and screening, or evidence of active malignancy, were also excluded. Written informed consent was obtained from all patients recruited, or written assent from a relative. Clinical history, examination, medications and Oxfordshire Community Stroke Project (OCSP) classification [28] were recorded at baseline. Computed tomography (CT) brain scan (IGE CT Pace Plus 3^rd generation scanner, IGE Medical Systems Ltd, Milwaukee, WI) was performed within 24 hours of admission to exclude patients with stroke mimic or primary intracerebral haemorrhage (PICH). Blood pressure, pulse rate and aural temperature (Braun Thermoscan LF20 digital thermometer) were recorded at all visits. At 3 and 12 months, additional medical history, changes in medication history and general clinical examination were also recorded. Infections were recorded prospectively during the study period wherever possible, using all available clinical information and investigation results. In the case of suspected infections preceding the index stroke, information was gathered from history and clinical records.

Thirty-seven patients with ischaemic stroke were recruited between April 2000 and January 2001. Baseline characteristics and medications for the 37 patients at entry are presented in Table 1. Median (minimum, maximum) time from onset of stroke symptoms to recruitment was 5 (1.5 to 11.75) hours. Stroke characteristics and outcome measures are presented in Table 2. The number of patients at each visit is outlined in Figure 1. Two patients had documented infections (both respiratory), and one, a proven myocardial infarction within the six weeks preceding their index stroke. A further 7 had definite infections (four respiratory, two urinary and one peripheral cannula site), within the first week after the index stroke. One other patient developed sepsis during the first week, with no focus identified. Three patients died prior to the 5 to 7 day assessment (including the patient with the preceding myocardial infarction) leaving 34 patients with peak values of plasma IL-6, CRP, cortisol and aural temperature for analysis. Peak WBC count values were available in 32, and peak ESR in 27 of these patients. Of the fourteen patients (38%) who died by 12 months, causes of death were certified as index stroke in eight, recurrent stroke in one, sepsis in three, pulmonary embolus in one, and left ventricular failure secondary to preceding myocardial infarction in another.

In the present study, we report that peak plasma IL-6 concentration in the first week of ischaemic stroke correlated significantly with CT brain infarct volume at 5 to 7 days, and clinical outcome at 3 months. Secondary analyses also demonstrated strong associations between peak plasma IL-6 and stroke severity, clinical outcome, or mortality at 12 months. In keeping with these findings, other peripheral markers of inflammation, including peak plasma CRP, WBC count, ESR or plasma cortisol, were associated with severity of stroke, CT brain infarct volume or clinical outcome.

We reasoned that a good estimate of the magnitude of the peripheral inflammatory response would be obtained by taking the peak value of measurements within the first 24 hours of stroke, or at the end of the first week. We accept that it is difficult to determine the true peak without continuous or multiple serial measurements. Furthermore, only patients with data at all timepoints, and those surviving to day 5 to 7 could be included in analysis of peak values, therefore excluding patients that died within the first week who may have had the most severe strokes. Previous studies have reported peak values of serum IL-6 within the first 10 days of stroke [13, 15, 18, 33], but only two related peak IL-6 to outcome measures, with neither defining primary analyses. Our data confirm the strong correlation between peak serum IL-6 with CT infarct volume or stroke severity [13, 15]. We have extended these findings by demonstrating, for the first time, strong correlations between peak plasma IL-6 with measures of clinical outcome at 3 and 12 months. Furthermore, to our knowledge, we are the first to report association between individual peak values of plasma CRP concentration, ESR or WBC count within the first week of ischaemic stroke, and CT brain infarct volume or outcome.

We did not exclude stroke patients with preceding or concurrent inflammatory conditions, as it may be argued that findings are more useful if applicable to a generalised population of patients, and that a systemic inflammatory response to infection might contribute to poor outcome. We may have underestimated the number of our patients with infection, as we did not apply predetermined criteria for defining, or investigating, infectious episodes. However, this also applies to previous studies of inflammation and stroke where patients with infection were said to have been excluded. Nevertheless, after performing post-hoc analysis of our patients, excluding those with inflammatory conditions in the six weeks preceding, or during the first week of index stroke, correlations between peak plasma IL-6, CRP or WBC count and outcome were only moderately reduced.

The question arises as to whether IL-6 might directly contribute to infarct pathogenesis, or is simply a marker of CNS, or indeed other, inflammatory injury. On the one hand, IL-6 has several pro-inflammatory effects [10, 34‐37] which may contribute to the induction and evolution of early inflammatory injury in the brain and its vasculature. Furthermore, IL-6 is up-regulated by the proinflammatory cytokines interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α) [38]. In experimental cerebral ischaemia, there is considerable evidence implicating IL-1β in cerebral injury [39], although TNF-α may have both deleterious and protective effects [40]. On the other hand, IL-6 also has neurotrophic [41], and anti-inflammatory effects [42] which may also be important after cerebral ischaemia.

An important consideration is whether peripheral markers of inflammation relate to outcome independent of stroke severity or brain infarct volume. IL-6 concentration independently predicts early neurological deterioration [14], and CRP concentration independently predicts survival, after ischaemic stroke [22, 24‐26]. We could not use a multifactorial model to address whether peak plasma IL-6 concentration related to outcome independently of stroke severity or infarct size due to the limitation of our sample size and insufficient power.

Despite the ability of IL-6 to induce fever or activate the HPA axis, peak plasma IL-6 concentration only correlated weakly with peak aural temperature or peak plasma cortisol concentration (data not shown). Peak aural temperature correlated weakly with brain infarct volume, stroke severity or outcome, in contrast to previous studies [23, 43]. However, it is unclear from these previous reports how many patients received antipyretics in relation to measurements of temperature. In our study, a high proportion of stroke patients received aspirin (300 mg), paracetamol, or both, in the first week of stroke, which may have affected observed aural temperature readings. Peak plasma cortisol concentration correlated modestly with CT brain infarct volume, stroke severity or outcome, in agreement with previous studies [19, 44, 45].

We have demonstrated significant correlations between peak plasma IL-6 in the first week of ischaemic stroke with both brain infarct volume and outcome at 3 months. Secondary analyses supported the relationship between peripheral inflammatory markers and both the extent of tissue injury, and clinical outcome to 12 months. Peripheral inflammatory markers may provide useful prognostic information in patients with acute ischaemic stroke, and pharmacological modulation of the inflammatory response may provide the basis for novel acute neuroprotective therapies for use in patients with cerebral ischaemia.